Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Preparation of oxidized sodium alginate-graft-poly((2-dimethylamino) ethyl methacrylate) gel beads and in vitro controlled release behavior of BSA

      , , , ,
      International Journal of Pharmaceutics
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Graft copolymerization of amino group-terminated poly((2-dimethylamino) ethyl methacrylate) (PDMAEMA-NH2) onto oxidized sodium alginate (OSA) was reacted without using a catalyst. The structure of the graft was investigated by Fourier transform infrared (FT-IR) spectroscopy. The OSA-g-PDMAEMA gel beads were prepared by dropping the aqueous solution of the graft copolymer into CaCl2 aqueous solution. The effects of pH and ionic strength on the swelling behaviors of the gel beads were studied. The results indicate that the gel beads have pH and ionic strength sensitivity. Bovine serum albumin (BSA) was entrapped in the beads and the in vitro drug release profiles were established in buffer solution with pH 1.8 (HCl), pH 7.4 (KH2PO4-NaOH), and 0.9% (w/v) NaCl at 37 degrees C. The results showed that the oral delivery of proteins can be controlled by adjusting the graft percentage (G, %), pH and ionic strength. According to this study, the OSA-g-PDMAEMA gel beads could be suitable for the oral delivery of proteins.

          Related collections

          Author and article information

          Journal
          International Journal of Pharmaceutics
          International Journal of Pharmaceutics
          Elsevier BV
          03785173
          April 2009
          April 2009
          : 371
          : 1-2
          : 16-24
          Article
          10.1016/j.ijpharm.2008.12.013
          19135513
          c34b2610-5ec6-4f91-a205-347a33e43bd6
          © 2009

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article